Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia and Schizoaffective Disorder Clear all
Completed No phase listed Observational

Effects of Antipsychotic Medications on Energy Intake and Expenditure

NCT00836251
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Weight Gain
Interventions
H218O and 2H2O, administered as a mixed cocktail
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

NCT07116694
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation
Interventions
BXCL501 Sublingual Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Chino, California • Oceanside, California • Orange, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 1Phase 2 Interventional

Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia

NCT01292577
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
CET/PT, Treatment as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study

NCT02642029
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I
Interventions
Excitatory TMS, Inhibitory TMS, Sham TMS
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Belmont, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Jul 24, 2026, 2:12 AM EDT
Recruiting Phase 3 Interventional

Cognitive Strategies in Early Psychosis 2

NCT07263022
View directory record Official record
Conditions
Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features, Bipolar Disorder With Psychotic Features, Psychosis NOS, Schizophreniform Disorder, Psychotic Disorder, Cognition
Interventions
Modafinil, D-serine solution, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 24, 2026, 2:12 AM EDT
Recruiting No phase listed Observational

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified, Early Psychosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Not applicable Interventional

Financial Incentives to Improve Medication Adherence

NCT04191876
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depression
Interventions
Wellth - Financial Incentives
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

NCT02237235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
MMFS-202-302, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders

NCT00001656
View directory record Official record
Conditions
Childhood Schizophrenia, Psychotic Disorder, Schizophrenia
Interventions
Olanzapine, Clozapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Results available

A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder

NCT00621777
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
Birmingham, Alabama • Bloomington, Indiana • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

NCT00088465
View directory record Official record
Conditions
Schizophrenic Disorders, Schizoaffective Disorder
Interventions
Intramuscular olanzapine depot
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 76 Years
Enrollment
931 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
21
States / cities
Orange, California • Pasadena, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Jul 24, 2026, 2:12 AM EDT
Recruiting Not applicable Interventional

Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33)

NCT06865937
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder
Interventions
Mobile Intervention for Social Recovery in Serious Mental Illness (mSITE), Supportive Contact (SC)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

NCT00690274
View directory record Official record
Conditions
Schizophrenia
Interventions
BF2.649, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jul 24, 2026, 2:12 AM EDT
Recruiting Phase 4 Interventional

CLOZAPINE Response in Biotype-1

NCT04580134
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Interventions
clozapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders

NCT00650611
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
17
States / cities
San Diego, California • Altamonte Springs, Florida • Libertyville, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Not applicable Interventional Results available

Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness

NCT03208036
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizo Affective Disorder
Interventions
TDCS, Sham Stimulation, Cognitive Remediation, Bridging Group
Device · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Jul 24, 2026, 2:12 AM EDT
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 4 Interventional

Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin

NCT00177580
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Pravastatin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jul 24, 2026, 2:12 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCT02462473
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jul 24, 2026, 2:12 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Obstructive Sleep Apnea Treatment in Serious Mental Illness

NCT05457127
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Obstructive Sleep Apnea of Adult
Interventions
Automatic Positive Airway Pressure (APAP)
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Early Phase 1 Interventional

Cognitive Effects of Nimodipine in Patients With Schizophrenia

NCT03671525
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Nimodipine, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 3 Interventional

Broad Effectiveness: Study With Aripiprazole

NCT00036361
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Not applicable Interventional Results available

Clinical Trial of Dipyridamole in Schizophrenia

NCT00349973
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Dipyridamole, Olanzapine
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole for Bipolar Disorder and Alcohol Use Disorder

NCT02918370
View directory record Official record
Conditions
Bipolar Disorder, Alcoholism, Alcohol Abuse
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 24, 2026, 2:12 AM EDT